BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 20737510)

  • 1. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M
    Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma.
    Plavina T; Berman M; Njenga M; Crossman M; Lerner M; Gorelik L; Simon K; Schlain B; Subramanyam M
    J Clin Virol; 2012 Jan; 53(1):65-71. PubMed ID: 22104399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
    Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
    Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
    Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C; Richman S; Plavina T; Natarajan A; Scanlon JV; Subramanyam M; Sandrock A; Bloomgren G
    Ann Neurol; 2011 Nov; 70(5):742-50. PubMed ID: 22162056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
    Bozic C; Subramanyam M; Richman S; Plavina T; Zhang A; Ticho B
    Eur J Neurol; 2014 Feb; 21(2):299-304. PubMed ID: 24894998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assay to quantify species-specific anti-JC virus antibody levels in MS patients.
    Warnke C; Pawlita M; Dehmel T; Posevitz-Fejfar A; Hartung HP; Wiendl H; Kieseier BC; Adams O
    Mult Scler; 2013 Aug; 19(9):1137-44. PubMed ID: 23388163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
    Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
    Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
    Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.